ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer has sued Israel's Teva Pharmaceutical Industries to prevent it from selling a generic version of Viagra. Teva has conditional FDA approval to market sildenafil citrate, pending both the expiration of a Pfizer patent in March 2012 and the outcome of this new patent litigation. In its lawsuit Pfizer claims the generic version would infringe on another patent that doesn't expire until October 2019. In 2009, Pfizer's sales of the erectile dysfunction drug were $1.9 billion.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter